Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of M7824 in Advanced Solid Tumors
NCT02517398Phase 1Completed
- Sponsor
- EMD Serono
- Start
- Aug 2015
- Primary completion
- May 2022
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 12
01
Overview
Phase 1, open-label, single-arm trial of bintrafusp alfa in solid tumor, glioblastoma (GBM), non-small cell lung cancer (NSCLC) and 5 more, sponsored by EMD Serono. Primary endpoints: Treatment-emergent Adverse Events up to 139 weeks, Dose-Limiting Toxicities up to 21 days and 2 more. Started Aug 2015; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
solid tumorglioblastoma (GBM)non-small cell lung cancer (NSCLC)biliary tract cancer (BTC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02517398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02517398.